# Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

> **NCT02348450** · PHASE4 · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 308 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Etoposide
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02348450
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-02
- **Final completion:** 2018-12
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348450, "Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02348450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*